TITLE

Health professionals' and service users' perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trial

AUTHOR(S)
Townsend, D.; Reeves, B. C.; Taylor, J.; Chakravarthy, U.; O'Reilly, D.; Hogg, R. E.; Mills, N.
PUB. DATE
April 2015
SOURCE
BMJ Open;Apr2015, Vol. 5 Issue 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
102613709

 

Related Articles

  • Early Data Put Kibosh on Opko's Bevasiranib Trial.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p3 

    The article reports on the drop in the shares of Opko Health Inc. based in Miami, Florida, when it announced last March 6, 2009 that it will put into end its Phase III trial of bevasiranib. The company's shares have dropped 11 cents to close at 80 cents after its monitoring committee determined...

  • Early Data Put Kibosh on Opko's Bevasiranib Trial.  // BioWorld Today;3/9/2009, Vol. 20 Issue 44, p2 

    The article reports that the shares of Opko Health Inc. dropped 11 percent after it announced that it was ending its Phase III trial of bevasiranib, designed to be a first-in-class small interfering RNA (siRNA). The decision to end the trial came after a data monitoring committee determined the...

  • Regeneron, Bayer Start Phase III With VEGF Trap-Eye In Wet AMD. Morrison, Trista // BioWorld Today;8/6/2007, Vol. 18 Issue 151, p1 

    The article reports on the pivotal procedure launched by Regeneron Pharmaceuticals Inc. and partner Bayer HealthCare AG for VEGF Trap-Eye with a Phase III trial comparing the drug to Lucentis (ranibizumab, Genentech Inc.) in wet age-related macular degeneration (wet AMD). The study is designed...

  • HOME MONITORING FOR AMD MAY HAVE SUBSTANTIAL IMPACT ON U.S. PUBLIC HEALTH. Charters, Lynda // Ophthalmology Times;Sep2015, Vol. 40 Issue 15, p39 

    The article looks at the results of a study on the use of a home-monitoring device to monitor patients at high risk for wet age-related macular degeneration (AMD). Topics mentioned include the importance of early identification of individuals at risk for developing AMD, identification of the...

  • Regeneron Stock Up 19.7% After Positive VEGF Trap-Eye Report. Wall, Tom // BioWorld Today;11/23/2010, Vol. 21 Issue 227, p1 

    The article reports that stock price in Regeneron Pharmaceuticals Inc. increased by 4.86 U.S. dollars to 29.53 U.S. dollars following the release of data from the company and partner Bayer HealthCare on two parallel Phase III studies of VEGF Trap-Eye. Primary endpoints were met in the trials...

  • Aflibercept no added benefit in AMD, says IQWiG.  // PharmacoEconomics & Outcomes News;4/1/2013, Issue 675, p11 

    The article reports that the Institute for Quality and Efficiency in Health Care (IQWiG) states that Aflibercept provides no additional benefit for standard therapy in wet age-related macular degeneration (AMD).

  • NICE recommends Eylea for wet AMD.  // Optometry Today;6/14/2013, Vol. 53 Issue 12, p7 

    The article places emphasis on an announcement by the British National Institute for Health and Care Excellence (NICE) that the medicine Eylea should be recommended for the treatment of patients with wet age-related macular degeneration (AMD) in England and Wales.

  • Phase III study tests options for wet AMD.  // Ophthalmology Times;10/15/2002, Vol. 27 Issue 20, p8 

    Focuses on the phase III study tests for wet age-related macular degeneration by Alcon Research Ltd. in Fort Worth, Texas. Effects of photodynamic therapy on the treatment of macular degeneration; Increase in number of patients in Alcon; Sites of the clinical trials.

  • Using Avastin for wet AMD 'could save NHS £84.5m.'.  // Optometry Today;5/18/2012, Vol. 52 Issue 10, p5 

    The article discusses a research study which found that the use of Avastin instead of Lucentin for treating patients with wet age-related macular degeneration (AMD) can help the National Health Service (NHS) save 84.5 million pounds per year.

  • Action on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient care. Amoaku, W; Blakeney, S; Freeman, M; Gale, R; Johnston, R; Kelly, S P; McLaughlan, B; Sahu, D; Varma, D // Eye;Feb2012 Supplement, Vol. 26, pS2 

    In recent years, there have been significant advances in the clinical management of patients with wet age-related macular degeneration (wet AMD)-a rapidly progressing and potentially blinding degenerative eye disease. Wet AMD is responsible for more than half of registered severe sight...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics